All News

In JAMA, Christakis, MD, MPH exposes IDD mental health gaps—better screening, counseling access, and training for disabilities.

FDA approves dupilumab for allergic fungal rhinosinusitis ages 6+, cutting sinus blockage, polyps and smell loss while sharply reducing repeat surgery and steroid use.

In a phase 2 trial in China, UBT251 led to up to 19.7% mean weight loss at 24 weeks vs 2.0% with placebo in adults with overweight or obesity.

Swallowable gastric balloon, approved by the FDA, provides a non-invasive, surgery-free weight loss solution for patients with a BMI between 30 and 40.

In the REDEFINE 4 trial, CagriSema led to 23% weight loss at 84 weeks but did not demonstrate noninferiority to tirzepatide 15 mg in adults with obesity.

Explore new epinephrine options—nasal spray and sublingual film—designed to boost carry-and-use rates and treat anaphylaxis faster.

Learn severe anaphylaxis warning signs, key risk factors and how to recognize infant reactions—plus when to use epinephrine and seek ER care.

Learn why epinephrine stops anaphylaxis fast, when a second dose matters, and who can safely monitor at home after treatment.

New anaphylaxis guidance shifts care toward rapid epinephrine, fewer steroids and antihistamines, and smarter ED decisions for children and adults.

New anaphylaxis guidance urges early recognition, epinephrine-first treatment, and smarter referrals.

In 142 000 adults, adding Galleri to standard screening reduced stage IV diagnoses over time in a prespecified group of 12 cancers, according to new data.

SMART trial finds clesrovimab protects high-risk children in a second RSV season, with consistent safety and fewer RSV-related hospitalizations.

Phase 3 data from KALOS and LOGOS trial support triple therapy in uncontrolled asthma, for both adolescents and adults.

A new study with infants reveals that those from vegetarian households follow growth trajectories nearly identical to their omnivorous peers by the age of 2.

Real-world data show GSK’s Arexvy is linked to 75.6% lower hospitalization risk in adults ≥60, with reduced CV events and COPD exacerbations.

Data show 44-week durable clinical remission in ulcerative colitis and endoscopic response in Crohn disease with duvakitug, a TL1A-targeting monoclonal antibody now in phase 3 trials.

Cardiologist Payal Kohli, MD, emphasizes the need to address racial and ethnic disparities in CKD screening, particularly among African Americans, Hispanics, women, and older adults.

ACP’s Carney urges primary care physicians to drop “provider,” saying American College of Physicians sees it eroding trust, ethics, and physician identity.